HONG KONG/CHINA (Yosefardi) – The Lippo Group, one of the largest conglomerates and the biggest healthcare provider in Indonesia, through its affiliate Venturra Capital, signed a Memordandum of Understanding (MoU) with Prenetics™, a Personalized & Precision Medicine Life Sciences company based in Hong Kong.

Under the terms of the MoU, Venturra Capital will invest an undisclosed amount in the USD millions into Prenetics. In addition, the Lippo Group will act as a strategic partner for an initial period of 5-Years to offer personalized & precision medicine in Indonesia.

Prenetics has developed its proprietary iGenes Pharmacogenomics test. Pharmacogenomics is the study of how genes affects a person’s response to drugs. iGenes is a non-invasive, saliva based test with a report ready to physicians within 48 hours. The iGenes report will identify the right drug, at the right dosage, tailored to a patient’s genetic make-up.

Lippo Group Director and Managing Partner of Venturra Capital, John Riady, sid precision medicine is the future of healthcare which today needs reform as it is expensive, reactive, inefficient and focused largely on one-size fits-all treatments for chronic illness and cancer. An answer is personalized, predictive, and preventive medicine.